An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.
Inclusion Criteria
For inclusion in this trial, patients must fulfill all of the following criteria:
Exclusion Criteria
Any of the following will exclude a patient from entering the trial:
Chule Vista, California, United States
LaVerne, California, United States
Marina Del Ray, California, United States
Royal Grande, California, United States
Twentynine Palm, California, United States
Handen, Connecticut, United States
Ormand Beach, Florida, United States
Tripler AMC, Hawaii, United States
Flossmore, Illinois, United States
Witchita, Kansas, United States
Debque, Louisiana, United States
Thiodaux, Louisiana, United States
Worchester, Massachusetts, United States
Battle Kreek, Michigan, United States
Golfport, Michigan, United States
Grosse Point Woods, Michigan, United States
Poplar Buff, Michigan, United States
Creve Coeus, Missouri, United States
Wiliamsville, New York, United States
Finley, Ohio, United States
Klamath, Oregon, United States
Cellarsville, Pennsylvania, United States
Langhorn, Pennsylvania, United States
Spartenburg, South Carolina, United States
Fredricksburg, Texas, United States
Walla Walla, Texas, United States
Abington, Virginia, United States